|
09 Oct 2025
|
Rubicon Research
|
ICICI Direct
|
|
|
|
|
IPO Note
|
|
|
Rubicon is one of the fastest growing Indian pharmaceutical companies focusing completely on the US market which contributed ~99% of the FY25 revenues. It has a pipeline of 17 products under review with the USFDA and...
|
|
09 Oct 2025
|
Rubicon Research
|
Hem Securities
|
|
|
|
|
IPO Subscribe
|
|
|
Company is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of seven listed Indian companies assessed by F&S, and Company), company is the only Indian pharmaceutical player with a complete focus on regulated markets. Between Fiscals 2023 and 2025, company was...
|
|
08 Oct 2025
|
Rubicon Research
|
Ventura
|
|
|
|
|
IPO Subscribe
|
|
|
|
|
06 Oct 2025
|
Rubicon Research
|
SBI Securities
|
|
|
|
|
IPO Note
|
|
|
Rubicon Research Ltd (RRL) is an innovation-driven and R&D focused pharmaceutical formulations company with an increasing portfolio of specialty products and drug-device combination products concentrated in USA (~99.6% of 1QFY26 revenue). As of Jun'25, its product portfolio included 72 active Abbreviated New Drug Applications (ANDAs), 9 active New Drug Applications (NDAs) and 1 Over-the-Counter (OTC) monography listed with the United States Food & Drug Administration (USFDA), which includes 16 specialty products. During FY25, RRL held a market share of...
|